By Ed Frankl 
 

Novartis AG said Wednesday that European regulators approved its lung-cancer treatment Tabrecta.

The Swiss pharmaceutical company said the European Commission approved Tabrecta, also known as capmatinib, as a single-drug treatment of adults with certain advanced nonsmall cell lung cancers.

The approval, based on a Phase 2 trial, follows a positive opinion issued in April by the European Medicines Agency, Novartis said.

The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein, the Basel, Switzerland-based company said.

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

June 22, 2022 01:50 ET (05:50 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2022 até Out 2022 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2021 até Out 2022 Click aqui para mais gráficos Novartis.